AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26246443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 24012493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral TAP block with 0.5% ropivacaine
Number of subjects: 51
Study 24012493 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 51
Study 21517204 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous practice with the interruption task
Number of subjects: 0
Study 21517204 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous practice with specific primary and interruption task-pair
Number of subjects: 0
Study 21517204 — intervention group
Group type: COMPARATOR
Intervention: Experience with other primary and interruption task-pairs or practice on the primary task alone
Number of subjects: 0
Study 18358117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile adherent film used during CVC insertion
Number of subjects: 100
Study 18358117 — intervention group
Group type: COMPARATOR
Intervention: Current hospital protocol for CVC insertion
Number of subjects: 100
Study 16554448 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 0.6 mg/kg ideal body weight
Number of subjects: 10
Study 12929058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin transnasal (UT) EGD
Number of subjects: 200
Study 12929058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin oral (UO) EGD
Number of subjects: 200
Study 12929058 — intervention group
Group type: COMPARATOR
Intervention: Standard (SO) EGD
Number of subjects: 200
Study 10908136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle data recorders
Number of subjects: 840
Study 10908136 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-equipped vehicles)
Number of subjects: 840
Study 9379783 — intervention group
Group type: COMPARATOR
Intervention: Dotarizine 50 mg (single dose)
Number of subjects: 16
Study 9379783 — intervention group
Group type: COMPARATOR
Intervention: Dotarizine 100 mg (single dose)
Number of subjects: 16
Study 9379783 — intervention group
Group type: COMPARATOR
Intervention: Dotarizine 200 mg (single dose)
Number of subjects: 16
Study 9379783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotarizine 50 mg (twice daily for 14 days)
Number of subjects: 16
Study 1588379 — intervention group
Group type: EXPERIMENTAL
Intervention: AG plus HC (250 mg AG twice a day, 20 mg HC twice a day)
Number of subjects: 153
Study 1588379 — intervention group
Group type: COMPARATOR
Intervention: AG (250 mg AG twice a day)
Number of subjects: 153
Study 1588379 — intervention group
Group type: EXPERIMENTAL
Intervention: AG plus HC
Number of subjects: 153
Study 1588379 — intervention group
Group type: COMPARATOR
Intervention: AG
Number of subjects: 153
Study 3838405 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg, sublingually administered)
Number of subjects: 7
Study 3838405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sublingually administered)
Number of subjects: 7
Study 30658621 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Acceptance and Commitment Therapy (ACT) intervention delivered over 7 weeks
Number of subjects: 100
Study 30658621 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 100
Study 29072800 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily
Number of subjects: 32
Study 29072800 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 32
Study 26952225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Number of subjects: 0
Study 26952225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 24666619 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 1352
Study 24666619 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 1352
Study 22730105 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy (flexible-dose for 8 weeks)
Number of subjects: 28
Study 22730105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20205704 — intervention group
Group type: EXPERIMENTAL
Intervention: One year low‐intensity computer‐tailored energy balance programme
Number of subjects: 413
Study 20205704 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 413
Study 18700217 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured risk assessment following admission with mandatory evaluation of prevention in high-risk patients
Number of subjects: 14
Study 18700217 — intervention group
Group type: COMPARATOR
Intervention: Control wards (no structured risk assessment)
Number of subjects: 14
Study 18700217 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured risk assessment
Number of subjects: 14
Study 15972022 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CIHD
Number of subjects: 20
Study 15972022 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 12788576 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG (ATCC 53103)
Number of subjects: 107
Study 12788576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 10483607 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/m2 calcium folinate
Number of subjects: 16
Study 10483607 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 calcium folinate
Number of subjects: 16
Study 10483607 — intervention group
Group type: COMPARATOR
Intervention: 650 mg/m2/d fluorouracil
Number of subjects: 16
Study 8724043 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin 40 mg/m2 every 2 weeks for 12 weeks
Number of subjects: 29
Study 8724043 — intervention group
Group type: COMPARATOR
Intervention: Observation for 12 weeks
Number of subjects: 29
Study 8724043 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin
Number of subjects: 29
Study 1929343 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin-clavulanate combination
Number of subjects: 109
Study 1929343 — intervention group
Group type: COMPARATOR
Intervention: 3-day regimen of amoxicillin-clavulanate
Number of subjects: 109
Study 6749280 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU and hydroxyurea for one year
Number of subjects: 865
Study 6749280 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 865
Study 30746581 — intervention group
Group type: EXPERIMENTAL
Intervention: Yisaipu® tapering (50 mg every other week from week 13 to week 24)
Number of subjects: 136
Study 30746581 — intervention group
Group type: COMPARATOR
Intervention: Full-dose therapy (50 mg/week for the entire study duration)
Number of subjects: 136
Study 28371248 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted group administered antibiotics based on bile culture results
Number of subjects: 126
Study 28371248 — intervention group
Group type: COMPARATOR
Intervention: Standard group administered cefmetazole
Number of subjects: 126
Study 28371248 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted group (specific procedures: pancreaticoduodenectomy)
Number of subjects: 126
Study 28371248 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted group (specific procedures: hepatectomy)
Number of subjects: 126
Study 26410119 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (VRET) with social interactions; two exposure sessions
Number of subjects: 34
Study 23568017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax‐AWS Airway Scope (AWS‐I)
Number of subjects: 23
Study 23568017 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope (ATQ)
Number of subjects: 23
Study 23568017 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope
Number of subjects: 23
Study 23568017 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller laryngoscope and Airtraq laryngoscope (ATQ)
Number of subjects: 23
Study 21332852 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal Scrub method
Number of subjects: 60
Study 21332852 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bass method
Number of subjects: 60
Study 21332852 — intervention group
Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 60
Study 19515296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (parenting handbook + BASICS)
Number of subjects: 1275
Study 19515296 — intervention group
Group type: COMPARATOR
Intervention: Parent intervention only
Number of subjects: 1275
Study 19515296 — intervention group
Group type: COMPARATOR
Intervention: BASICS only
Number of subjects: 1275
Study 19515296 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 1275
Study 16690793 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute plasma volume expansion (APVE)
Number of subjects: 8
Study 16690793 — intervention group
Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 8
Study 15256675 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor therapy (perindopril, 4 mg daily)
Number of subjects: 19
Study 15256675 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 19
Study 11778855 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide whitening solution
Number of subjects: 0
Study 9402352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg q.d. for 6 weeks)
Number of subjects: 122
Study 9402352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg q.d. for 6 weeks) with amoxicillin (500 mg t.i.d.) and metronidazole (500 mg b.i.d.) for the first 12 days
Number of subjects: 122
Study 9402352 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (120 mg q.i.d. for 6 weeks) with amoxicillin and metronidazole (at same dosages as in group B)
Number of subjects: 122
Study 9402352 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-eradicated H. pylori)
Number of subjects: 122
Study 9402352 — intervention group
Group type: COMPARATOR
Intervention: Control group (eradicated H. pylori)
Number of subjects: 122
Study 9402352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine with amoxicillin and metronidazole (group B)
Number of subjects: 122
Study 9402352 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate with amoxicillin and metronidazole (group C)
Number of subjects: 122
Study 7966736 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage hypospadias repair using a preputial free graft for neourethral construction and a preputial pedicle flap for ventral skin coverage
Number of subjects: 77
Study 3036903 — intervention group
Group type: COMPARATOR
Intervention: no dexamethasone (DEX), enflurane anesthesia
Number of subjects: 25
Study 3036903 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg DEX, iv, 45-60 min before sternotomy, enflurane anesthesia
Number of subjects: 25
Study 3036903 — intervention group
Group type: COMPARATOR
Intervention: no DEX, fentanyl anesthesia (50-100 micrograms/kg)
Number of subjects: 25
Study 3036903 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX, fentanyl anesthesia
Number of subjects: 25
Study 31728664 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 4 mg (DRSP)
Number of subjects: 858
Study 31728664 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel 0.075 mg (DSG)
Number of subjects: 858
Study 28699562 — intervention group
Group type: EXPERIMENTAL
Intervention: Camino Verde intervention
Number of subjects: 90
Study 26325644 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical debridement (SD)
Number of subjects: 21
Study 26325644 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical debridement (NSD)
Number of subjects: 21
Study 23247002 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 588
Study 23247002 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 588
Study 23247002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 588
Study 23247002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 23247002 — intervention group
Group type: EXPERIMENTAL
Intervention: A/C
Number of subjects: 588
Study 21540755 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 42
Study 21540755 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 42
Study 21540755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18500152 — intervention group
Group type: EXPERIMENTAL
Intervention: CaviStat mint confection (BasicMints)
Number of subjects: 200
Study 18500152 — intervention group
Group type: COMPARATOR
Intervention: Sugarless mint control (without CaviStat)
Number of subjects: 200
Study 16504528 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-thoracoscopy (VT)
Number of subjects: 24
Study 16504528 — intervention group
Group type: COMPARATOR
Intervention: Transaxillary thoracotomy (TT)
Number of subjects: 24
Study 16504528 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral thoracotomy (PLT)
Number of subjects: 24
Study 15504627 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TSE machine
Number of subjects: 8
Study 15504627 — intervention group
Group type: COMPARATOR
Intervention: Inactive TSE machine
Number of subjects: 8
Study 11269770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure bandage
Number of subjects: 420
Study 11269770 — intervention group
Group type: COMPARATOR
Intervention: No pressure bandage
Number of subjects: 420
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric advanced life support (PALS) training
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic life support training
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric advanced life support (PALS) training for support staff
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of intraosseous needles
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of endotracheal tubes
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of oxygen tanks
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of intravenous catheters
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of nebulizers
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of epinephrine 1:1,000
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of calcium chloride
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency plans designed by pediatricians
Number of subjects: 240
Study 9715220 — intervention group
Group type: EXPERIMENTAL
Intervention: Conducting mock drills
Number of subjects: 240
Study 7912442 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible white light (10,000 lux)
Number of subjects: 35
Study 7912442 — intervention group
Group type: COMPARATOR
Intervention: Visible red light (175 lux)
Number of subjects: 35
Study 7912442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both light treatment conditions
Number of subjects: 35
Study 2660552 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 76
Study 2660552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g twice daily
Number of subjects: 76
Study 31719527 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation
Number of subjects: 72
Study 28392369 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Chest Compression (CCC) CPR
Number of subjects: 14109
Study 28392369 — intervention group
Group type: COMPARATOR
Intervention: 30:2 CPR
Number of subjects: 14109
Study 26226173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser at 3 W, 30 mJ per pulse, contact mode, 300 μm diameter optic fiber
Number of subjects: 20
Study 26226173 — intervention group
Group type: COMPARATOR
Intervention: Surgical stripping
Number of subjects: 20
Study 26226173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 20
Study 22733833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice a day, switching to 110 mg twice a day at age 80)
Number of subjects: 65
Study 22733833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 65
Study 22733833 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 65
Study 21054671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 9
Study 21054671 — intervention group
Group type: EXPERIMENTAL
Intervention: Eformoterol
Number of subjects: 9
Study 19934816 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 50
Study 19934816 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 50
Study 19934816 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 16467663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg daily for 6 months)
Number of subjects: 80
Study 16467663 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg daily for 6 months)
Number of subjects: 80
Study 15164111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk consumption >500 g/day
Number of subjects: 94
Study 15164111 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk consumption <500 g/day
Number of subjects: 94
Study 15164111 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from birth to 2 years
Number of subjects: 94
Study 15164111 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-depleted children
Number of subjects: 94
Study 11285325 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 40
Study 11285325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 40
Study 11285325 — intervention group
Group type: EXPERIMENTAL
Intervention: Linola oil
Number of subjects: 40
Study 9292585 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant gp160 (r-gp160) immunization
Number of subjects: 76
Study 8308770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiinflammatory drug (NSAID) therapy
Number of subjects: 26
Study 2962333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide 0.05 mg
Number of subjects: 8
Study 2962333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide 0.5 mg
Number of subjects: 8
Study 2962333 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.25 mg
Number of subjects: 8
Study 2962333 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 2.5 mg
Number of subjects: 8
Study 2962333 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 29776961 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 1122
Study 27002215 — intervention group
Group type: EXPERIMENTAL
Intervention: C-SASS (SASS delivered by school counselors)
Number of subjects: 138
Study 27002215 — intervention group
Group type: EXPERIMENTAL
Intervention: P-SASS (SASS delivered by psychologists)
Number of subjects: 138
Study 27002215 — intervention group
Group type: COMPARATOR
Intervention: Control (Skills for Life - SFL)
Number of subjects: 138
Study 25902142 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-to-fake condition
Number of subjects: 65
Study 25902142 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 65
Study 23562005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine
Number of subjects: 40
Study 23562005 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 40
Study 20399986 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/d plus telmisartan 80 mg/d (RT group)
Number of subjects: 151
Study 20399986 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg/d plus irbesartan 300 mg/d (RI group)
Number of subjects: 151
Study 20399986 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg/d plus olmesartan 20 mg/d (RO group)
Number of subjects: 151
Study 17884266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment in patients with schizophrenia
Number of subjects: 53
Study 17884266 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment using the Schizophrenia Quality of Life Scale
Number of subjects: 53
Study 17884266 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning
Number of subjects: 53
Study 17884266 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy in QOL
Number of subjects: 53
Study 17884266 — intervention group
Group type: EXPERIMENTAL
Intervention: Social knowledge and memory
Number of subjects: 53
Study 15730920 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutritional support
Number of subjects: 40
Study 15730920 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutritional support
Number of subjects: 40
Study 14527091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegetarian diet
Number of subjects: 18
Study 14527091 — intervention group
Group type: COMPARATOR
Intervention: High-fat non-vegetarian diet
Number of subjects: 18
Study 14527091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat vegetarian diet
Number of subjects: 18
Study 14527091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat non-vegetarian diet
Number of subjects: 18
Study 11320434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rarely Missed Index (RMI) calculated from the Logical Memory Delayed Recognition (LMDR) items
Number of subjects: 137
Study 11320434 — intervention group
Group type: COMPARATOR
Intervention: Logical Memory Delayed Recognition (LMDR) subtest
Number of subjects: 137
Study 8844448 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily for 9 days)
Number of subjects: 12
Study 8844448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1384438 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 45